The better play is to buy right through. And we made good money each and every day. That has always been my tactic. 1847 Goedeker Inc. (GOED) 20% gummy!!! Who loves ya! NYSE American - Nasdaq Real Time Price. Currency in USD $3.9100+0.5800 (+17.42%)<------- At close: 4:00PM EDT 4.0700 +0.16 (4.09%)<------
This Eldorado may be public-- they make a heck of hydrogen bus!! Where does REV come in? I don't get it.
Only 20% of Americans familiar with NFTs, 4 million have used: Survey Ihsaan Fanusie June 8, 2021, 12:50 PM·2 min read Less than a quarter of American adults are familiar with Non-Fungible Tokens (NFTs), according to a new Security.org survey, a percentage significantly less than previous estimates. The report, released on June 3, surveyed over 500 adults. It found that 66% of people had never heard of NFTs before the survey, while 14% had heard of them but were unsure of what they were. Around 2% of respondents had purchased or sold an NFT in the past. Half of those “familiar” were able to define an NFT, and an additional 15% believed them to be a cryptocurrency, such as bitcoin (BTC-USD).
Confusing set up> Word kind of out? CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021 CymaBay Therapeutics, Inc. June 21, 2021, 8:00 AM·7 min read New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced positive data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC). These data are being presented at The International Liver Congress™ 2021 of the European Association for the Study of Liver (EASL) which will be held online June 23rd – 26th. In a poster presentation titled “Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies,”1 Stuart C. Gordon MD, Director of Hepatology for Henry Ford Health Systems, will be reporting the results of a pooled analysis of a subset of 39 patients with compensated cirrhosis from an open-label phase 2 study and a placebo (Pbo) controlled phase 3 study... A 3 month update which was positive has preceded this- you never say never but it would be very hard to have bad news. Does that stymie the move?
The Great Sha'Carri!!! Van you tell Anastassia she better start working out and stop sulking in your garage. This five foot one Diva Dynamo is my favorite sprinter-- OLYMPIC THREAD WATCH OUT!!! Dynamite! Possible GBA Board member....
Am I Diversified-? 2:33 mark. There is one African American at this company. Run by an Indian guy. Nerdy not so diverse.